CL
LGND icon

Choreo LLC’s Ligand Pharmaceuticals LGND Stock Holding History

Choreo LLC’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$502K Buy
1,587
+17
+1% +$4.01K 0.01% 994
2026
Q1 		$313K Buy
1,570
+166
+12% +$32.8K ﹤0.01% 1227
2025
Q4 		$267K Sell
1,404
-214
-13% -$41.1K ﹤0.01% 1286
2025
Q3 		$287K Buy
+1,618
New +$241K ﹤0.01% 1254

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Choreo LLC's LGND Position: Q2 2026 in Review

Choreo LLC increased its Ligand Pharmaceuticals (LGND) stake by 1.1% in Q2 2026, buying an estimated $4.01K and bringing the position to 1,587 shares worth $502K. The position accounts for 0.01% of the portfolio, ranked #994.

Choreo LLC first reported a position in LGND in Q3 2025 and has held it in 4 quarters since. 417 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Choreo LLC held 1,587 shares of Ligand Pharmaceuticals worth $502K as of Q2 2026.
  • Choreo LLC bought 17 Ligand Pharmaceuticals shares in Q2 2026, an estimated $4.01K.
  • Ligand Pharmaceuticals made up 0.01% of Choreo LLC's portfolio in Q2 2026, its #994 holding.
  • Choreo LLC first reported a position in Ligand Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • 417 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Choreo LLC's 13F filing for Q2 2026, filed 4 Aug 2026.